Take the acid test.
Consider these
questions carefully, because your
answers may reveal the need to further optimize your
treatment approach.
Answer these questions about
H. pylori treatment
Are any of your patients failing on their current H. pylori regimen?
You’re not alone. 1 out of 5 patients fails H. pylori therapy.1,2
Learn MoreTest your patients before and after treatment, because 1 out of 5 patients fails H. pylori therapy.
Learn MoreThat is fortunate, but you may want to test your patients before and after treatment, because 1 out of 5 patients fails H. pylori therapy.
Learn MoreAre you concerned that inadequate acid suppression may be contributing to treatment failure?
Concerned
Concerned
Concerned
Your concern is valid, because growth-dependent antibiotics work best against actively dividing H. pylori bacteria when gastric pH is from 6 to 8.3
Learn MoreYou’re on to something, because growth-dependent antibiotics work best against actively dividing H. pylori bacteria when gastric pH is from 6 to 8.3
Learn MoreIt may be worth taking a closer look, because growth-dependent antibiotics work best against actively dividing H. pylori bacteria when gastric pH is from 6 to 8.3
Learn MoreAre complicated dosing schedules making adherence difficult for some of your patients?
Treatment often includes a large number of pills with confusing dosing instructions. Further, the need to take most PPIs 30-60 minutes before a meal can present challenges for patients.4-6
Learn MoreIt’s something to be aware of. Treatment often includes a large number of pills with confusing dosing instructions. Further, the need to take most PPIs 30-60 minutes before a meal can present challenges for patients.4-6
Learn MoreConsider asking them. Treatment often includes a large number of pills with confusing dosing instructions. Further, the need to take most PPIs 30-60 minutes before a meal can present challenges for patients.4-6
Learn More Answer these questions about
erosive esophagitis treatment
Do you have any patients with recurring erosive esophagitis?
You’re not alone. Recurrences occur in ~71-80% of patients within 6 months of PPI discontinuation.7-10
Learn MoreConsider testing regularly, because recurrences occur in ~71-80% within 6 months of PPI discontinuation.7-10
Learn MoreConsider testing before and after treatment, because recurrences occur in ~71-80% of patients within 6 months of PPI discontinuation.7-10
Learn MoreIs erosive esophagitis causing complications for your patients?
You’re likely aware that complications can include respiratory problems, chest pain, and even esophageal cancer.6,11,12
Learn MoreIt’s important to know, because complications can include respiratory problems, chest pain, and even esophageal cancer.6,11,12
Learn MoreYou may want to probe deeper. Complications can include respiratory problems, chest pain, and even esophageal cancer.6,11,12
Learn MoreCould treatment challenges be getting in the way of complete healing for patients?
It’s not uncommon. Most PPIs require dosing 30-60 minutes before a meal, which can present challenges for patients.
Learn MoreIt’s something to be aware of. Most PPIs require dosing 30-60 minutes before a meal, which can present challenges for patients.
Learn MoreConsider asking them. Most PPIs require dosing 30-60 minutes before a meal, which can present challenges for patients.
Learn MoreReferences:
- 1.Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212-239. doi:10.1038/ajg.2016.563
- 2.Alsamman MA, Vecchio EC, Shawwa K, Acosta-Gonzales G, Resnick MB, Moss SF. Retrospective analysis confirms tetracycline quadruple as best Helicobacter pylori regimen in the USA. Dig Dis Sci. 2019;64(10):2893-2898. doi:10.1007/s10620-019-05694-4
- 3.Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori Infection: expert review. Gastroenterology. 2021;160(5):1831-1841. doi:10.1053/ j.gastro.2020.11.059
- 4.Solem C, Mody R, Stephens J, Macahilig C, Gao X. Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: physician knowledge, patient adherence. J Am Pharm Assoc (2003). 2014;54(2):144-153. doi:10.1331/JAPhA.2014.13117
- 5.Mermelstein J, Mermelstein AC, Chait MM. Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole. Clin Exp Gastroenterol. 2016;9:163-172. doi:10.2147/CEG.S91602
- 6.Dickman R, Maradey-Romero C, Gingold-Belfer R, Fass R. Unmet needs in the treatment of gastroesophageal reflux disease. J Neurogastroenterol Motil. 2015;21(3):309-319. doi:10.5056/jnm15105
- 7.Katzka DA, Kahrilas PJ. Advances in the diagnosis and management of gastroesophageal reflux disease. BMJ. 2020;371:m3786. doi:10.1136/bmj.m3786
- 8.Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988;95(4):903-912. doi:10.1016/0016-5085(88)90162-x
- 9.Metz DC, Howden CW, Perez MC, Larsen L, O’Neil J, Atkinson SN. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther. 2009;29(7):742-754. doi:10.1111/j.1365-2036.2009.03954.x
- 10.Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther. 2001;15(7):927-935. doi:10.1046/j.1365-2036.2001.01024.x
- 11.Scholten T. Long-term management of gastroesophageal reflux disease with pantoprazole. Ther Clin Risk Manag. 2007;3(2):231-243. doi:10.2147/tcrm.2007.3.2.231
- 12.Ruigómez A, García Rodríguez LA, Wallander MA, Johansson S, Graffner H, Dent J. Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther. 2004;20(7):751-760. doi:10.1111/j.1365-2036.2004.02169.x